Using blood markers to improve treatment for metastatic pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the understanding of pancreatic cancer treatment response by analyzing small molecules called miRNAs in the blood of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The research focuses on patients starting treatment with the FOLFIRINOX regimen, utilizing liquid biopsy techniques to collect blood samples for miRNA analysis. By identifying specific miRNA expression patterns, the study seeks to predict treatment effectiveness and enable personalized therapeutic adjustments, ultimately improving patient outcomes. The approach combines cost-effective qPCR methods with innovative liquid biopsy technology to facilitate early detection of treatment responses and disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with metastatic PDAC;
* Patients who will start treatment with FOLFIRINOX;
* 18 years or older;
* Who agree to participate in the study by signing the Informed Consent Form;

Exclusion Criteria:

* Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
* Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;

Where it's running

• A Beneficência Portuguesa de São Paulo
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Study coordinator: Camila Farias
• Email: camila.farias@bp.org.br
• Phone: +551135054680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• KLF4 Epigenetic Modulation in Colorectal Tissue

  Researchers will look at how the KLF4 gene’s methylation changes as colorectal tissue moves from polyps to more advanced lesions to see if this reflects or relates to gene activity.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT07901335

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.